• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by MBX Biosciences Inc.

    7/8/26 10:11:21 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MBX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    MBX BIOSCIENCES INC

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)




    55287L101

    (CUSIP Number)
    06/30/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    55287L101


    1Names of Reporting Persons

    FMR LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    5,322,706.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    5,322,884.68
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,322,884.68
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    11.2 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP Number(s):
    55287L101


    1Names of Reporting Persons

    Abigail P. Johnson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    5,322,884.68
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,322,884.68
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    11.2 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    MBX BIOSCIENCES INC
    (b)Address of issuer's principal executive offices:

    11711 N. MERIDIAN STREET,SUITE 300,CARMEL,IN,USA,46032
    Item 2. 
    (a)Name of person filing:

    FMR LLC
    (b)Address or principal business office or, if none, residence:

    245 Summer Street, Boston, Massachusetts 02210
    (c)Citizenship:

    Not applicable
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    55287L101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    5322884.68
    (b)Percent of class:

    11.2  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Please see the responses to Items 5 and 6 on the cover page.

     (ii) Shared power to vote or to direct the vote:

    0.00

     (iii) Sole power to dispose or to direct the disposition of:

    5322884.68

     (iv) Shared power to dispose or to direct the disposition of:

    0.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of MBX BIOSCIENCES INC. No one other person's interest in the COMMON STOCK of MBX BIOSCIENCES INC is more than five percent of the total outstanding COMMON STOCK.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See attached Exhibit 99.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    FMR LLC
     
    Signature:Richard Bourgelas
    Name/Title:Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
    Date:07/07/2026
     
    Abigail P. Johnson
     
    Signature:Richard Bourgelas
    Name/Title:Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of Abigail P. Johnson*
    Date:07/07/2026

    Comments accompanying signature:  *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on April 29,2026, accession number: 0000315066-26-000738.
    Exhibit Information

    Please see Exhibit 99 for 13d-1(k) (1) agreement.

    Get the next $MBX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MBX

    DatePrice TargetRatingAnalyst
    1/28/2026$66.00Overweight
    Barclays
    12/4/2025$18.00Sell
    Goldman
    11/4/2025Buy
    TD Cowen
    10/15/2025$50.00Buy
    Truist
    8/15/2025$36.00Buy
    Jefferies
    8/5/2025$38.00Outperform
    Mizuho
    7/16/2025$38.00Outperform
    Oppenheimer
    4/10/2025$38.00Mkt Outperform
    Citizens JMP
    More analyst ratings

    $MBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Mathers Edward T

    4 - MBX Biosciences, Inc. (0001776111) (Issuer)

    6/5/26 2:35:37 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Pescovitz Ora H.

    4 - MBX Biosciences, Inc. (0001776111) (Issuer)

    6/5/26 7:59:21 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Heron Patrick J

    4 - MBX Biosciences, Inc. (0001776111) (Issuer)

    6/5/26 7:59:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    SEC Filings

    View All

    SEC Form 8-K filed by MBX Biosciences Inc.

    8-K - MBX Biosciences, Inc. (0001776111) (Filer)

    7/13/26 4:46:20 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by MBX Biosciences Inc.

    SCHEDULE 13G/A - MBX Biosciences, Inc. (0001776111) (Subject)

    7/8/26 12:59:14 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by MBX Biosciences Inc.

    SCHEDULE 13G/A - MBX Biosciences, Inc. (0001776111) (Subject)

    7/8/26 10:11:21 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Hawryluk P. Kent bought $525,663 worth of shares (18,500 units at $28.41) (SEC Form 4)

    4 - MBX Biosciences, Inc. (0001776111) (Issuer)

    3/16/26 8:02:03 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Hawryluk P. Kent bought $272,790 worth of shares (20,000 units at $13.64) (SEC Form 4)

    4 - MBX Biosciences, Inc. (0001776111) (Issuer)

    10/21/25 5:43:44 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hoerter Steven L. bought $264,984 worth of shares (20,000 units at $13.25) (SEC Form 4)

    4 - MBX Biosciences, Inc. (0001776111) (Issuer)

    10/20/25 4:44:37 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Attovia Therapeutics Appoints John W. Smither to Board of Directors

    SAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced the appointment of John W. Smither to its Board of Directors as an independent director and as Chair of the Audit Committee. "We are pleased to welcome John to our Board," said Tao Fu, Founder and Chief Executive Officer of Attovia. "John is a proven leader in guiding biotechnology companies through critical stages of development. Having served as Chief Financial Officer across multiple public and private biotechnology companies,

    7/15/26 8:30:00 AM ET
    $MBX
    $ARQT
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth

    CARMEL, Ind. and BURLINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that its Board of Directors has appointed Steve Hoerter, current Executive Chairman of the Board, as its new Chairman and Chief Executive Officer. Mr. Hoerter succeeds Kent Hawryluk, who will step down as President, Chief Executive Officer and a member of the Board of Directors. In addition, the Board has appointed John Smither, current Interim Chief Financial Officer, as the C

    7/13/26 4:15:00 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

    Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial Results consistent with restoration of systemic PTH activity through serum calcium normalization, reduction of urine calcium excretion, restoration of bone metabolism and increase of eGFR (a measure of kidney function) High retention rate with 90% of patients entering the OLE remaining in the study at one year Canvuparatide was generally well tolerated with no new safety signals during the OLE PK supports once-weekly dosing, with low peak-to-trough ratio and stable exposure Phase 3 pivotal trial remains on track to initiate in Q3 2026 Company to host conference call tod

    6/12/26 7:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on MBX Biosciences with a new price target

    Barclays initiated coverage of MBX Biosciences with a rating of Overweight and set a new price target of $66.00

    1/28/26 7:18:07 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on MBX Biosciences with a new price target

    Goldman initiated coverage of MBX Biosciences with a rating of Sell and set a new price target of $18.00

    12/4/25 8:45:53 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on MBX Biosciences

    TD Cowen initiated coverage of MBX Biosciences with a rating of Buy

    11/4/25 7:44:06 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by MBX Biosciences Inc.

    SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)

    11/8/24 10:52:39 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by MBX Biosciences Inc.

    SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)

    11/1/24 5:38:56 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by MBX Biosciences Inc.

    SC 13D - MBX Biosciences, Inc. (0001776111) (Subject)

    9/23/24 6:07:21 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Financials

    Live finance-specific insights

    View All

    MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

    Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial Results consistent with restoration of systemic PTH activity through serum calcium normalization, reduction of urine calcium excretion, restoration of bone metabolism and increase of eGFR (a measure of kidney function) High retention rate with 90% of patients entering the OLE remaining in the study at one year Canvuparatide was generally well tolerated with no new safety signals during the OLE PK supports once-weekly dosing, with low peak-to-trough ratio and stable exposure Phase 3 pivotal trial remains on track to initiate in Q3 2026 Company to host conference call tod

    6/12/26 7:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026

    CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will host an investor webcast and conference call at 8:00 am ET on Friday, June 12, 2026 to discuss presentations for once-weekly canvuparatide at the upcoming Endocrine Society's Annual Meeting (ENDO 2026) in Chicago. One-year open-label extension (OLE) data from the Phase 2 trial of once-weekly canvuparatide will be presented at the 3rd Parathyroid Summit during ENDO 2026 on Friday, June

    6/1/26 8:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

    Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE) Positive findings in bone and kidney biomarkers All patients completed the 12-week AvailTM trial and 94% entered the OLE Once-weekly canvuparatide was generally well tolerated, with no treatment-related serious adverse events or discontinuations during the 12-week trial Preparation underway to initiate Phase 3 trial in 2026 Company to host conference call at 8:00 am ET today CARMEL, Ind., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on

    9/22/25 7:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Leadership Updates

    Live Leadership Updates

    View All

    Attovia Therapeutics Appoints John W. Smither to Board of Directors

    SAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced the appointment of John W. Smither to its Board of Directors as an independent director and as Chair of the Audit Committee. "We are pleased to welcome John to our Board," said Tao Fu, Founder and Chief Executive Officer of Attovia. "John is a proven leader in guiding biotechnology companies through critical stages of development. Having served as Chief Financial Officer across multiple public and private biotechnology companies,

    7/15/26 8:30:00 AM ET
    $MBX
    $ARQT
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights

    Results from Phase 2 trial of once-weekly canvuparatide accepted for oral presentation at ENDO in June 2026 Phase 3 trial of once-weekly canvuparatide on track to initiate in Q3 2026 Appointment of Mark Soued as Chief Commercial Officer adds launch and commercialization expertise Company to host Obesity Day on May 11th featuring initial blinded data from ongoing MBX 4291 Phase 1 trial and update on expanding obesity portfolio $440.0 million in cash and investments expected to support operations into 2029 CARMEL, Ind. and BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, developme

    5/7/26 8:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award

    CARMEL, Ind. and BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Mark R. Soued, MBA, as Chief Commercial Officer (CCO). Mr. Soued brings more than two decades of commercial leadership across global biopharmaceutical organizations, with deep expertise in product launches, market access, and building high-performing commercial teams. "Mark is an exceptional commercial leader with a demonstrated ability to build and scale c

    5/7/26 7:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care